Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Bernzott Capital Advisors

Bernzott Capital Advisors raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 8.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 101,760 shares of the biopharmaceutical company's stock after acquiring an additional 7,775 shares during the period. Halozyme Therapeutics makes up approximately 3.2% of Bernzott Capital Advisors' investment portfolio, making the stock its 13th largest position. Bernzott Capital Advisors owned about 0.08% of Halozyme Therapeutics worth $6,493,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Avantax Advisory Services Inc. increased its holdings in shares of Halozyme Therapeutics by 23.2% during the 4th quarter. Avantax Advisory Services Inc. now owns 9,766 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 1,839 shares during the last quarter. Cibc World Markets Corp acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth $558,000. Xponance Inc. lifted its position in shares of Halozyme Therapeutics by 6.0% during the 4th quarter. Xponance Inc. now owns 18,454 shares of the biopharmaceutical company's stock worth $882,000 after purchasing an additional 1,051 shares during the last quarter. Vinva Investment Management Ltd purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $138,000. Finally, Teacher Retirement System of Texas lifted its position in shares of Halozyme Therapeutics by 17.5% during the 4th quarter. Teacher Retirement System of Texas now owns 37,516 shares of the biopharmaceutical company's stock worth $1,794,000 after purchasing an additional 5,594 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on HALO shares. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the stock a "neutral" rating in a report on Wednesday. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a report on Tuesday, May 13th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Hold" and an average price target of $62.70.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the transaction, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,497 shares of company stock valued at $3,533,884 over the last 90 days. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Down 0.8%

HALO stock traded down $0.47 on Friday, hitting $57.34. 163,020 shares of the company were exchanged, compared to its average volume of 1,745,758. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The business's fifty day moving average is $54.48 and its two-hundred day moving average is $57.15. The stock has a market capitalization of $7.07 billion, a price-to-earnings ratio of 15.25, a price-to-earnings-growth ratio of 0.39 and a beta of 1.15. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The business's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.79 earnings per share. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.